A large real-world study involving more than 430,000 adults aged 65 years and older found comparable effectiveness between adjuvanted and high-dose influenza vaccines, reinforcing current ACIP recommendations and giving health care systems greater flexibility during vaccine procurement and influenza season planning. In this Q&A, Mendel Haag, PhD, senior director of the Center of Outcomes Research & Epidemiology in global medical affairs at CSL Seqirus, discusses vaccine confidence, influenza misinformation, operational barriers to vaccination, and why ongoing real-world evidence remains critical for protecting vulnerable older adult populations.